Follow-On Biologics Process May Allow Post-Approval Immunogenicity Tests

A regulatory process for follow-on biologics could allow for post-approval immunogenicity testing, FDA Office of Biotechnology Products Principal Advisor for Regulatory Science & Review Anthony Mire-Sluis, PhD, suggested

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet